Conditions: Breast Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 77
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: BMS-754807 intervention 2: letrozole
Intervention descriptions: intervention 1: Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity intervention 2: Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity

Protocol document: